The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Disparities in access to CAR-T and BsAb therapy for multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the challenges in accessing novel therapies including CAR-T and bispecific antibodies for multiple myeloma, highlighting the racial and socioeconomic disparities for African American and Hispanic patients in the US. Dr Sidana comments on the stringent eligibility criteria for clinical trials evaluating these therapies and the lack of available slots at medical centers offering CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
